INTELLIGENCE: SEVEN POTENTIAL BIOTECH BUYOUT TARGETS IN WAKE OF ARIAD BUYOUT $ARIA $BMRN $EXEL $FOLD $INCY $MDVN $RARE $SGEN $TSRO

Twitter
LinkedIn
Facebook

INTELLIGENCE: SEVEN POTENTIAL BIOTECH BUYOUT TARGETS IN WAKE OF ARIAD BUYOUT $ARIA $BMRN $EXEL $FOLD $INCY $MDVN $RARE $SGEN $TSRO

This post was just published on ZYX Buy Change Alert.

For us to recommend, a stock must pass at least four of the six screens. We prefer a stock to meet all six screens. Our rigorous criteria has led to enviable performance over a long period of time. We periodically provide intelligence on trades that we do not recommend, but our subscribers may be able to take advantage.

Previously our subscribers benefited handsomely from buyout of MDVN.  MDVN was long from $55.50 and the stock was tendered at $81.50 producing an annualized return of 149%.  In the wake of MDVN buyout, we published a post INTELLIGENCE: EIGHT POTENTIAL BUYOUT TARGETS IN THE WAKE OF MDVN BUYOUT .

ARIA was on the top of that list and now it has produced 237% gain for some of our subscribers.  The following seven stocks still remain prime buyout targets.

BMRN

EXEL

FOLD

INCY

RARE

SGEN

TSRO

All of these seven companies that are not in the portfolio are on our radar.  We are likely to issue official buy signals with buy zones, target zones and stop zones in due course when our strict criteria is met.

In the interim, in response to the last post, some of our sophisticated subscribers already purchased a basket of these stocks.  Sophisticated subscribers who are aggressive may consider purchasing a basket of these seven stocks with small quantities on pullbacks as our stringent criteria to give official signals may not be met.

Trades posted on The Arora Report Market Blog have produced unrivalled performance since 2007.  Please click here and scroll down to see the table of all trades.  These trades have been scrutinized in real-time by thousands of subscribers across the globe.  This provides easy verification of performance for newcomers to this site.  Only those trades are included in the performance where the entry post was made available to subscribers to The Arora Report Market Blog.  When the entry post is made available only to the paying subscribers and not posted in real-time on The Arora Report Market Blog, the resulting performance of the trade is not credited in the performance table.  There are very nice gains on these trades but since the entry trade was not posted here in real-time, handsome profits on these trades will not be added to the performance of The Arora Report Market Blog shown on the table.

You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES.

Please click here to take advantage of a FREE  30 day trial.

Check out our enviable performance in both bull and bear markets.

Subscribe to 'Generate Wealth'

Free Forever

More To Explore

30 Day Free Trial

Cancel within 30 days and you owe nothing

When you take a FREE 30 day trial, you get access to powerful techniques used by billionaires and hedge funds to grow richer. You can continue to use these powerful techniques to grow richer even if you cancel your subscription. You come out ahead by subscribing no matter how you look at it.

A fortune is to be made from AI stocks.
Get the list of 18 AI stocks to grab your share of the profits — no cost to you.

A fortune is to be made from AI stocks.

Get the list of 18 AI stocks to grab your share of the profits.

AI is a $1 Trillion Market

Making A Fortune
In Artificial Intelligence

Golden Age of Artificial Intelligence